Largest health care biotech companies by market cap
Amgen leads the 24 health care biotech companies ranked by market value, at NOK 2.33T, ahead of Gilead Sciences (NOK 2.03T) and Moderna (NOK 772.4B). Figures as of 19 Nov 2026, 00:22 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenNOK 2.33T
- Median
- NOK 103.1B
- Combined market value
- NOK 8.11T
- Countries
- 5
Market values as of .
All countries▾
Health Care▾
Biotech▾
| # | Company | Market cap ↓ | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | NOK 2.33T | NOK 4,305.65 | 3.07% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | NOK 2.03T | NOK 1,639.08 | 0.75% down | 33% up | ||
| 3 | ModernaMRNA · Health Care | NOK 772.4B | NOK 1,908.83 | 4.84% down | 755% up | ||
| 4 | argenxARGX · Health Care | NOK 574.1B | NOK 9,129.96 | 0.66% down | 4% up | ||
| 5 | BiogenBIIB · Health Care | NOK 360.5B | NOK 2,438.63 | 0.25% up | 49% up | ||
| 6 | Revolution MedicinesRVMD · Health Care | NOK 335.3B | NOK 1,550.23 | 1.76% down | 131% up | ||
| 7 | BioNTechBNTX · Health Care | NOK 200.2B | NOK 807.61 | 1.89% down | 16% down | ||
| 8 | ExelixisEXEL · Health Care | NOK 161.6B | NOK 662.40 | 0.31% down | 63% up | ||
| 9 | Neurocrine BiosciencesNBIX · Health Care | NOK 159.9B | NOK 1,579.71 | 1.84% down | 20% up | ||
| 10 | Bio-TechneTECH · Health Care | NOK 110.9B | NOK 705.66 | 0.17% up | 26% up | ||
| 11 | RepligenRGEN · Health Care | NOK 107.1B | NOK 1,674.87 | 6.47% up | 5% up | ||
| 12 | Halozyme TherapeuticsHALO · Health Care | NOK 105.9B | NOK 929.24 | 0.18% down | 37% up | ||
| 13 | Kymera TherapeuticsKYMR · Health Care | NOK 100.3B | NOK 1,174.94 | 0.32% down | 87% up | ||
| 14 | QiagenQGEN · Health Care | NOK 99.3B | NOK 480.72 | 0.38% down | 12% up | ||
| 15 | Krystal BiotechKRYS · Health Care | NOK 90.6B | NOK 3,058.74 | 5.62% up | 46% up | ||
| 16 | VaxcytePCVX · Health Care | NOK 89.9B | NOK 567.63 | 1.48% down | 22% up | ||
| 17 | Twist BioscienceTWST · Health Care | NOK 76.9B | NOK 1,128.57 | 3.88% up | 340% up | ||
| 18 | CG OncologyCGON · Health Care | NOK 69.3B | NOK 775.99 | 1.34% up | 85% up | ||
| 19 | ImmunityBioIBRX · Health Care | NOK 69.1B | NOK 64.99 | 7.03% up | 193% up | ||
| 20 | ImmunovantIMVT · Health Care | NOK 66.6B | NOK 321.74 | 0.12% down | 43% up | ||
| 21 | Kodiak SciencesKOD · Health Care | NOK 62B | NOK 948.74 | 1.04% up | 396% up | ||
| 22 | Scholar Rock HoldingSRRK · Health Care | NOK 56.8B | NOK 465.59 | 6.48% up | 14% up | ||
| 23 | Adaptive BiotechnologiesADPT · Health Care | NOK 44.7B | NOK 276.06 | 0.11% down | 88% up | ||
| 24 | CRISPR TherapeuticsCRSP · Health Care | NOK 37.8B | NOK 389.84 | 0.10% up | 21% down |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 9.6998 NOK).
Questions and answers
Which health care biotech companies rank first by market value?
Amgen (NOK 2.33T), Gilead Sciences (NOK 2.03T) and Moderna (NOK 772.4B) are the top three of the 24 health care biotech companies ranked by market value as of 19 Nov 2026, 00:22 UTC.
How many health care biotech companies are in this ranking?
24 are ranked by market value.
What are these health care biotech companies worth together?
The 24 health care biotech companies ranked by market value have a combined market value of NOK 8.11T as of 19 Nov 2026, 00:22 UTC.
What does ranking by market value measure?
What the stock market values the whole company at: its share price times the number of its shares.
Learn how this ranking works
All markets guides →- What market capitalization is, and what it is not
Market capitalization is the share price multiplied by the number of shares outstanding: 1 billion shares at $50 is a $50 billion company. It measures the size the stock market puts on a company's equity today. It is not a sale price, it ignores debt and cash, and index providers often count only the freely traded part, the float.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest health care biotech companies by market cap”, data as of 19 November 2026. https://funkfolio.com/companies/category/biotech?sector=health-care
Underlying data: Yahoo Finance; SEC EDGAR.